-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Meeting News
-
Meeting News for Nov. 23, 2022
IASLC selects multidisciplinary slate of physicians to chair WCLC 2024 and announces last call for abstracts for TTLC 2023.
-
In Brief for Nov. 9, 2022
Go2 Foundation coordinates educational events across the United States to improve lung cancer awareness; abstract submissions open for 2023 European Lung Cancer Congress; and registration begins for inaugural Texas Lung Cancer Conference.
-
Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice
During a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions.
-
IASLC Leadership Shares Experiences, Offers Advice for Women in Thoracic Oncology
During a networking panel at NACLC 22, CEO Karen Kelly and President Heather Wakelee joined program co-chairs Drs. Jessica Donington, Marina Chiara Garassino, and Jyoti Patel for a discussion with other women in the field.
-
In Brief for Oct. 26, 2022
Upcoming IASLC meetings offer educational opportunities around the globe. Read more for registration and abstract news from LACLC, ACLC, and TTLC.
-
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition
During IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC.
-
Researcher Reveals How Air Pollution May Cause Lung Cancer
During ESMO Congress 2022, Prof. Charles Swanton shared data that show cells with EGFR and KRAS gene mutations can turn cancerous when exposed to pollution from the burning of fossil fuels.
-
KEYNOTE-604 Follow-Up Results Continue to Show Clinically Meaningful Improvement
Long-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo.
-
Study Shows Shorter-Term Assessments Underestimate Pollution Exposure
During WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk.
-
POSEIDON Analysis Shows Sustained Benefit with Triplet Regimen Regardless of Mutational Status
Dr. Solange Peters showed 24-month overall survival rates were higher with tremelimumab, durvalumab, and chemotherapy versus chemotherapy alone across all subgroups, including those with KRAS, STK11, and KEAP1 mutations.